Global picture: Southeast Asia dengue season 2026 runs three weeks ahead of baseline

title: "Global picture: Southeast Asia dengue season 2026 runs three weeks ahead of baseline" date: "2026-04-02" author: "Mosticare Editorial" authorRole: "Vector Ecology · Mosticare Foundation" mins: 8 region: "Asia-Pacific" alert: null excerpt: "The 2026 dengue season across Southeast Asia is tracking three weeks ahead of the 2015–2024 baseline, with Thailand, Vietnam, and Indonesia all reporting record Q1 case counts. The European import implication is significant." sources:

• text: "WHO SEARO · Weekly dengue update, Week 13/2026" href: "https://www.who.int/docs/default-source/searo/thailand/2026-dengue-sitrep"
• text: "Thailand MoPH · Dengue situation report Q1 2026" href: "https://ddc.moph.go.th"
• text: "Messina et al. 2019 · The current and future global distribution and population at risk of dengue, Nature Microbiology" href: "https://doi.org/10.1038/s41564-019-0476-8"
• text: "Coudeville & Garnett 2012 · Transmission dynamics of dengue disease, PLOS ONE" href: "https://doi.org/10.1371/journal.pone.0045043" correctionEmail: "corrections@mosticare.org"

Dengue case counts across Southeast Asia in Q1 2026 are running at approximately 340% of the 2015–2024 Q1 average. Thailand has reported 94,000 cases in the first twelve weeks of the year, more than its full-year total for 2022. Vietnam and Indonesia are tracking similarly. The Philippines declared a national dengue outbreak on 14 March.

This is not unexpected. Dengue transmission follows a three-to-five year epidemic cycle driven by the depletion and replenishment of herd immunity against the four circulating serotypes. The 2022–2023 trough, itself inflated by reduced exposure during COVID mobility restrictions, has given way to a susceptible cohort of approximately 400 million people in the region with limited cross-serotype immunity.

Why the global baseline matters for Europe

The European import pipeline is directly upstream of the Southeast Asian case count. Thailand alone received approximately 4.2 million European visitors in Q1 2026, a combination of typical winter tourism and post-COVID travel recovery. Vietnam received approximately 1.6 million. Indonesia (primarily Bali) approximately 800,000.

A meaningful proportion of returning travellers are viraemic, in the 4–14 day incubation window, at the point of return. Most will be asymptomatic or mildly symptomatic and will not seek care until they are back home. A minority will be at peak viraemia at the time of return and will be a competent dengue source for any Aedes albopictus mosquito that bites them during their infectious period.

This is the import-to-autochthonous chain that produced Europe's first locally-acquired dengue outbreaks in the 2010s and has sustained them since. The higher the export caseload from Southeast Asia, the higher the import pressure on European Aedes albopictus populations in summer.

Which EU countries carry the highest import exposure

Flight route data and travel volume estimates for Q1 2026 suggest the following top-exposure EU countries for dengue imports from Southeast Asia:

1. France, largest tourist volume to Thailand and Vietnam, Roissy-CDG main hub
2. Germany, second-largest tourist volume; Frankfurt and Munich as entry hubs
3. Netherlands, Schiphol as a major transit hub for long-haul to Asia-Pacific
4. Spain, third-largest volume; Barajas hub
5. Italy, growing direct routes to Bangkok and Hanoi

These are also, not coincidentally, the countries with the most established Aedes albopictus populations in Europe. The alignment of high import pressure with established vector populations is the combination that produces autochthonous transmission chains.

The Brazilian secondary driver

Southeast Asia is the dominant source, but not the only one. Brazil's 2025–26 dengue epidemic has been the largest in the country's recorded history, with over 6 million cases by end-Q1 2026. Brazil is the largest non-EU tourism source for southern Europe, particularly Portugal, Spain, and Italy, and the DENV-3 strain circulating in Brazil is a serotype to which most European travellers have no prior immunity.

A returning traveller from Recife or São Paulo who is bitten by an Aedes albopictus in Lisbon, Barcelona, or Rome in the week after return is a viable index case for southern European transmission, at precisely the moment when vector densities are building toward their summer peak.

What this means for summer 2026

Mosticare's assessment is that the summer 2026 dengue season in southern Europe will be the most intensive since surveillance began, driven by:

1. Record global import pressure from Southeast Asia and Brazil
2. Established Aedes albopictus populations in all five highest-exposure countries
3. A warm spring that has accelerated the vector population ahead of seasonal norms in France, Italy, and Spain
4. A cohort of European travellers with below-average herd immunity following COVID-period travel restrictions

This does not mean Europe faces a dengue epidemic of Southeast Asian scale. The density of Aedes albopictus in Europe is orders of magnitude lower than in Bangkok or Jakarta. Transmission chains will be short and geographically confined in most cases.

It does mean that the number of autochthonous cases in 2026 will likely exceed the 2025 record, the first time that record has been broken in consecutive years. The infrastructure required to detect, trace, and contain these chains needs to be in place before July, not after the first case is confirmed.

Mosticare's threat map will track imported and autochthonous cases in real time across all 27 EU countries as the season progresses.